Drugs Made In America Acquisition Corp. (DMAA)

Blank Checks · market cap $263M · as of 2026-07-11

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Drugs Made In America Acquisition Corp. (DMAA) is a blank-check SPAC trading near its ~$10.66 NAV with a market cap of approximately $258M. Its stated lead asset is FS-1, a Phase 3 candidate for multidrug-resistant tuberculosis (MDR-TB), though mechanism, financials, and nearly all operational details are undisclosed. No upcoming catalysts are on the calendar and no analyst coverage exists.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
FS-1	Phase 3	Tuberculosis, MDR

Price & technical context

3-month

+1.3%

6-month

+1.9%

12-month

+4.8%

52-wk range

$10.02–$10.52

vs 50-day MA

+0.5%

vs 200-day MA

+1.7%

Realized vol

2.3%

Max drawdown

-0.5%

Daily closes through 2026-03-24. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for DMAA (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.